Dwarf-colony variants of Staphylococcus aureus resistant to aminoglucoside antibiotics and to a fatty acid.
D000085:Acetates / Q000378:metabolism; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001224:Aspartic Acid / Q000378:metabolism; D003470:Culture Media; D004352:Drug Resistance, Microbial; D005601:Framycetin / Q000494:pharmacology; D005632:Fructose / Q000378:metabolism; D005839:Gentamicins / Q000494:pharmacology; D006027:Glycosides / Q000494:pharmacology*; D006801:Humans; D007612:Kanamycin / Q000494:pharmacology; D008041:Linoleic Acids / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D009355:Neomycin / Q000494:pharmacology; D010071:Oxaloacetates / Q000378:metabolism; D010084:Oxidation-Reduction; D010303:Paromomycin / Q000494:pharmacology; D011773:Pyruvates / Q000378:metabolism; D012867:Skin / Q000382:microbiology; D013210:Staphylococcus / Q000187:drug effects* / Q000254:growth & development / Q000378:metabolism; D013307:Streptomycin / Q000494:pharmacology
D000085:Acetates; D000900:Anti-Bacterial Agents; D003470:Culture Media; D005839:Gentamicins; D006027:Glycosides; D008041:Linoleic Acids; D010071:Oxaloacetates; D011773:Pyruvates; D005632:Fructose; D001224:Aspartic Acid; D005601:Framycetin; D007612:Kanamycin; D010303:Paromomycin; D009355:Neomycin; D013307:Streptomycin